On Monday, Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) opened lower -7.25% from the last session, before settling in for the closing price of $2.07. Price fluctuations for ZNTL have ranged from $1.61 to $16.41 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted 44.92% at the time writing. With a float of $53.59 million, this company’s outstanding shares have now reached $71.15 million.
Let’s determine the extent of company efficiency that accounts for 168 employees. In terms of profitability, gross margin is 97.68%, operating margin of -490.5%, and the pretax margin is -419.76%.
Zentalis Pharmaceuticals Inc (ZNTL) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Zentalis Pharmaceuticals Inc is 24.81%, while institutional ownership is 87.48%. The most recent insider transaction that took place on Feb 06 ’25, was worth 45,656. In this transaction Chief Medical Officer of this company bought 20,000 shares at a rate of $2.28, taking the stock ownership to the 36,629 shares. Before that another transaction happened on Feb 11 ’25, when Company’s Former Director proposed sale 687 for $2.00, making the entire transaction worth $1,374.
Zentalis Pharmaceuticals Inc (ZNTL) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.66 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 44.92% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 18.52% during the next five years compared to -50.05% drop over the previous five years of trading.
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) Trading Performance Indicators
Check out the current performance indicators for Zentalis Pharmaceuticals Inc (ZNTL). In the past quarter, the stock posted a quick ratio of 7.29. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.37.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.53, a number that is poised to hit -0.69 in the next quarter and is forecasted to reach -2.52 in one year’s time.
Technical Analysis of Zentalis Pharmaceuticals Inc (ZNTL)
Looking closely at Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL), its last 5-days average volume was 0.79 million, which is a drop from its year-to-date volume of 2.22 million. As of the previous 9 days, the stock’s Stochastic %D was 10.42%. Additionally, its Average True Range was 0.25.
During the past 100 days, Zentalis Pharmaceuticals Inc’s (ZNTL) raw stochastic average was set at 10.95%, which indicates a significant increase from 5.30% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 79.06% in the past 14 days, which was lower than the 108.51% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.47, while its 200-day Moving Average is $4.18. However, in the short run, Zentalis Pharmaceuticals Inc’s stock first resistance to watch stands at $2.08. Second resistance stands at $2.23. The third major resistance level sits at $2.33. If the price goes on to break the first support level at $1.82, it is likely to go to the next support level at $1.72. Now, if the price goes above the second support level, the third support stands at $1.57.
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) Key Stats
There are currently 71,265K shares outstanding in the company with a market cap of 136.83 million. Presently, the company’s annual sales total 0 K according to its annual income of -292,190 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -88,280 K.
